Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020

Ahmed Sayed; Ann Marie Navar; Leandro Slipczuk; Christie M Ballantyne; Zainab Samad; Carl J Lavie; Salim S Virani

doi:10.1001/jamacardio.2023.3931

Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020

JAMA Cardiol. 2023 Dec 1;8(12):1185-1187. doi: 10.1001/jamacardio.2023.3931.

Authors

Ahmed Sayed¹, Ann Marie Navar^{2

3}, Leandro Slipczuk⁴, Christie M Ballantyne⁵, Zainab Samad⁶, Carl J Lavie⁷, Salim S Virani⁶

Affiliations

¹ Faculty of Medicine, Ain Shams University, Cairo, Egypt.
² Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
³ Deputy Editor, Diversity, Equity, and Inclusion, JAMA Cardiology.
⁴ Division of Cardiology, Montefiore Healthcare Network/Albert Einstein College of Medicine, New York, New York.
⁵ Department of Medicine, Baylor College of Medicine, Houston, Texas.
⁶ Department of Medicine, Aga Khan University, Karachi, Pakistan.
⁷ John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, Louisiana.

PMID: 37910086
PMCID: PMC10620668 (available on 2024-11-01)
DOI: 10.1001/jamacardio.2023.3931

No abstract available

Plain language summary

This cross-sectional study compares the prevalence, awareness, and treatment of elevated low-density lipoprotein (LDL) cholesterol in US adults in 1999-2000 vs 2017-2020.

MeSH terms

Adult
Cholesterol, LDL
Humans
Hypercholesterolemia* / drug therapy
Hypercholesterolemia* / epidemiology
Nutrition Surveys
Prevalence

Substances

Cholesterol, LDL